Molecular modeling studies of benzothiophene-containing derivatives as promising selective estrogen receptor downregulators: a combination of 3D-QSAR, molecular docking and molecular dynamics simulations

References

• Ashtekar, S. S., Bhatia, N. M., & Bhatia, M. S. (2018). Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain. Steroids, 131, 14–22. 10.1016/j.steroids.2017.12.016
   PubMed Web of Science ®Google Scholar
• Bentrem, D. J., Dardes, R. C., Liu, H., Macgregor-Schafer, J., Zapf, J. W., & Jordan, V. C. (2001). Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology, 142(2), 838–846. 10.1210/en.142.2.838
   PubMed Web of Science ®Google Scholar
• Bentzon, N., Düring, M., Rasmussen, B. B., Mouridsen, H., & Kroman, N. (2007). Prognostic effect of estrogen receptor status across age in primary breast cancer. International Journal of Cancer, 122(5), 1089–1094. 10.1002/ijc.22892
   Web of Science ®Google Scholar
• Bogliolo, S., Cassani, C., Dominoni, M., Orlandini, A., Ferrero, S., Iacobone, A. D., Viazzo, F., Venturini, P. L., Spinillo, A., & Gardella, B. (2017). The role of fulvestrant in endometrial cancer. Expert Opinion on Drug Metabolism & Toxicology, 13(5), 537–544. 10.1080/17425255.2016.1244264
   PubMed Web of Science ®Google Scholar
• Burks, H. E., Abrams, T., Kirby, C. A., Baird, J., Fekete, A., Hamann, L. G., Kim, S., Lombardo, F., Loo, A., Lubicka, D., Macchi, K., McDonnell, D. P., Mishina, Y., Norris, J. D., Nunez, J., Saran, C., Sun, Y., Thomsen, N. M., Wang, C., Wang, J., & Peukert, S. (2018). Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ERα+ breast cancer. Journal of Medicinal Chemistry, 60(7), 2790–2818. 10.1021/acs.jmedchem.6b01468
   Web of Science ®Google Scholar
• Carlson, R. W. (2005). The history and mechanism of action of fulvestrant. Clinical Breast Cancer, 6, S5–S8. 10.3816/cbc.2005.s.008
   PubMedGoogle Scholar
• Chai, T., & Draxler, R. R. (2014). Root mean square error (RMSE) or mean absolute error (MAE)? – Arguments against avoiding RMSE in the literature. Geoscientific Model Development, 7(3), 1247–1250. 10.5194/gmd-7-1247-2014
   Web of Science ®Google Scholar
• Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., Lee, P. W., & Tang, Y. (2012). admetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. Journal of Chemical Information and Modeling, 52(11), 3099–3105. 10.1021/ci300367a
   PubMed Web of Science ®Google Scholar
• Chinnasamy, S., Selvaraj, G., Kaushik, A. C., Kaliamurthi, S., Chandrabose, S., Singh, S. K., Thirugnanasambandam, R., Gu, K., & Wei, D.-Q. (2019). Evaluation of binding and antagonism/downregulation of brilanestrant molecule in estrogen receptor-α via quantum mechanics/molecular mechanics, molecular dynamics and binding free energy calculations. Journal of Biomolecular Structure and Dynamics, 38(1), 1–17. 10.1080/07391102.2019.1574605
   PubMed Web of Science ®Google Scholar
• Dai, Y.-H., Liao, L.-Z., & Li, D. (2004). On restart procedures for the conjugate gradient method. Numerical Algorithms, 35(2–4), 249–260. 10.1023/b:numa.0000021761.10993.6e
   Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 1–13. 10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Divakar, S., Santhoshkumar, M., Satvik, K., Ramachandra, S., Sasikumar, A., & Saravanan, J. (2020). Syringaresinol as a novel androgen receptor antagonist against wild and mutant androgen receptors for the treatment of castration resistant prostate cancer: Molecular docking, in-vitro and molecular dynamics study. Journal of Biomolecular Structure and Dynamics, 739–1102. 10.1080/07391102.2020.1715261
   Web of Science ®Google Scholar
• Dutertre, M., & Smith, C. L. (2000). Molecular mechanisms of selective estrogen receptor modulator (SERM) action. The Journal of Pharmacology and Experimental Therapeutics, 295(2), 431–437. 10.0000/PMID11046073.
   PubMed Web of Science ®Google Scholar
• Fedele, P., Orlando, L., Schiavone, P., Calvani, N., Caliolo, C., Quaranta, A., Nacci, A., & Cinieri, S. (2015). Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer. Critical Reviews in Oncology/Hematology, 94(3), 291–301. 10.1016/j.critrevonc.2015.01.001
   PubMed Web of Science ®Google Scholar
• Gasteiger, J., & Marsili, M. (1980). Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron, 36(22), 3219–3228. 10.1016/0040-4020(80)80168-2
   Web of Science ®Google Scholar
• Geetha Rani, Y., & Lakshmi, B. S. (2019). Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha. Journal of Biomolecular Structure and Dynamics, 37(5), 1189–1115. 10.1080/07391102.2018.1453378
   PubMed Web of Science ®Google Scholar
• Golbraikh, A., Shen, M., Xiao, Z., Xiao, Y.-D., Lee, K.-H., & Tropsha, A. (2003). Rational selection of training and test sets for the development of validated QSAR models. Journal of Computer-Aided Molecular Design, 17(2/4), 241–253. 10.1023/A:1025386326946
   PubMed Web of Science ®Google Scholar
• Golbraikh, A., & Tropsha, A. (2002a). Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. Journal of Computer-Aided Molecular Design, 16(5/6), 357–369. [Mismatch] 10.1023/a:1020869118689
   PubMed Web of Science ®Google Scholar
• Golbraikh, A., & Tropsha, A. (2002b). Beware of q2! Journal of Molecular Graphics and Modelling, 20(4), 269–276. 10.1016/S1093-3263(01)00123-1
   PubMed Web of Science ®Google Scholar
• Halim, S. A. (2015). Structure based 3D-QSAR studies of Interleukin-2 inhibitors: Comparing the quality and predictivity of 3D-QSAR models obtained from different alignment methods and charge calculations. Chemico-Biological Interactions, 238, 9–24. 10.1016/j.cbi.2015.05.018
   PubMed Web of Science ®Google Scholar
• Hamilton, E. P., Patel, M. R., Armstrong, A. C., Baird, R. D., Jhaveri, K., Hoch, M., Klinowska, T., Lindemann, J. P. O., Morgan, S. R., Schiavon, G., Weir, H. M., & Im, S.-A. (2018). A first-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER+/HER2 − advanced breast cancer. Clinical Cancer Research, 24(15), 3510–3518. 10.1158/1078-0432.ccr-17-3102
   PubMed Web of Science ®Google Scholar
• Howell, A., & Sapunar, F. (2011). Fulvestrant revisited: Efficacy and safety of the 500-mg dose. Clinical Breast Cancer, 11(4), 204–210. 10.1016/j.clbc.2011.02.002
   PubMed Web of Science ®Google Scholar
• Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015). ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nature Reviews Clinical Oncology, 12(10), 573–583. 10.1038/nrclinonc.2015.117
   PubMed Web of Science ®Google Scholar
• Johnston, S. R. D., & Dowsett, M. (2003). Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nature Reviews Cancer, 3(11), 821–831. 10.1038/nrc1211
   PubMed Web of Science ®Google Scholar
• Jordan, V. C. (2018). Tamoxifen resistance trumped and oral selective estrogen receptor degraders arrive. Clinical Cancer Research, 24(15), 3480–3482. 10.1158/1078-0432.ccr-18-0759
   PubMed Web of Science ®Google Scholar
• Lai, A., Kahraman, M., Govek, S., Nagasawa, J., Bonnefous, C., Julien, J., Douglas, K., Sensintaffar, J., Lu, N., Lee, K-j., Aparicio, A., Kaufman, J., Qian, J., Shao, G., Prudente, R., Moon, M. J., Joseph, J. D., Darimont, B., Brigham, D., … Smith, N. D. (2015). Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. Journal of Medicinal Chemistry, 58(12), 4888–4904. 10.1021/acs.jmedchem.5b00054
   PubMed Web of Science ®Google Scholar
• Lee, S., & Barron, M. G. (2018). 3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein–ligand interactions. Journal of Cheminformatics, 10(1), 1–13. 10.1186/s13321-017-0253-8
   PubMedGoogle Scholar
• Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Garnett, S., Lindemann, J. P. O., Sapunar, F., & Martin, M. (2010). Results of the CONFIRM phase III trial comparing Fulvestrant 250 mg with Fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer. Journal of Clinical Oncology, 28(30), 4594–4600. 10.1200/jco.2010.28.8415
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 64, 4–17. 10.1016/j.addr.2012.09.019
   Web of Science ®Google Scholar
• McDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015). Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer. Journal of Medicinal Chemistry, 58(12), 4883–4887. 10.1021/acs.jmedchem.5b00760
   PubMed Web of Science ®Google Scholar
• Milica, R., Dusan, R., Mirjana, A., Teodora, D., & Katarina, N. (2020). In silico identification of Novel 5-HT2A antagonists supported with ligand- and target- based drug design methodologies. Journal of Biomolecular Structure and Dynamics, 1–24. 10.1080/07391102.2020.1738961
   Web of Science ®Google Scholar
• Mills, J. N., Rutkovsky, A. C., & Giordano, A. (2018). Mechanisms of resistance in estrogen receptor positive breast cancer: Overcoming resistance to tamoxifen/aromatase inhibitors. Current Opinion in Pharmacology, 41, 59–65. 10.1016/j.coph.2018.04.009
   PubMed Web of Science ®Google Scholar
• Orlando, L., Schiavone, P., Fedele, P., Calvani, N., Nacci, A., Rizzo, P., Marino, A., D'Amico, M., Sponziello, F., Mazzoni, E., Cinefra, M., Fazio, N., Maiello, E., Silvestris, N., Colucci, G., & Cinieri, S. (2010). Molecularly targeted endocrine therapies for breast cancer. Cancer Treatment Reviews, 36, S67–S71. 10.1016/s0305-7372(10)70023-2
   PubMed Web of Science ®Google Scholar
• Ojha, P. K., & Roy, K. (2011). Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection. Chemometrics and Intelligent Laboratory Systems, 109(2), 146–161. 10.1016/j.chemolab.2011.08.007
   Web of Science ®Google Scholar
• Patel, H. K., & Bihani, T. (2018). Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacology & Therapeutics, 186, 1–24. 10.1016/j.pharmthera.2017.12.012
   PubMed Web of Science ®Google Scholar
• Pratim Partha, R., & Roy, K. (2008). On some aspects of variable selection for partial least squares regression models. QSAR & Combinatorial Science, 27(3), 302–313. 10.1002/qsar.200710043
   Google Scholar
• Ranjan, P., Athar, M., Jha, P. C., & Krishna, K. V. (2018). Probing the opportunities for designing anthelmintic leads by sub-structural topology-based QSAR modelling. Molecular Diversity, 22(3), 669–683. 10.1007/s11030-018-9825-4
   PubMed Web of Science ®Google Scholar
• Robertson, J. F. R., & Harrison, M. (2004). Fulvestrant: Pharmacokinetics and pharmacology. British Journal of Cancer, 90(S1), S7–S10. 10.1038/sj.bjc.6601630
   PubMedGoogle Scholar
• Romero-Parra, J., Chung, H., Tapia, R. A., Faúndez, M., Morales-Verdejo, C., Lorca, M., Lagos, C. F., Di Marzo, V., David Pessoa-Mahana, C., & Mella, J. (2017). Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. European Journal of Pharmaceutical Sciences, 101, 1–10. 10.1016/j.ejps.2017.01.037
   PubMed Web of Science ®Google Scholar
• Sharma, D., Kumar, S., & Narasimhan, B. (2018). Estrogen alpha receptor antagonists for the treatment of breast cancer: A review. Chemistry Central Journal, 12(1), 107. 10.1186/s13065-018-0472-8
   PubMedGoogle Scholar
• Shayanfar, A., & Shayanfar, S. (2014). Is regression through origin useful in external validation of QSAR models? European Journal of Pharmaceutical Sciences, 59, 31–35. 10.1016/j.ejps.2014.03.007
   PubMed Web of Science ®Google Scholar
• Tria, G. S., Abrams, T., Baird, J., Burks, H. E., Firestone, B., Gaither, L. A., Hamann, L. G., He, G., Kirby, C. A., Kim, S., Lombardo, F., Macchi, K. J., McDonnell, D. P., Mishina, Y., Norris, J. D., Nunez, J., Springer, C., Sun, Y., Thomsen, N. M., … Peukert, S. (2018). Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer. Journal of Medicinal Chemistry, 61(7), 2837–2864. 10.1021/acs.jmedchem.7b01682
   PubMed Web of Science ®Google Scholar
• Tropsha, A. (2010). Best practices for QSAR model development, validation, and exploitation. Molecular Informatics, 29(6–7), 476–488. 10.1002/minf.201000061
   PubMed Web of Science ®Google Scholar
• Vinter, J. G., Davis, A., & Saunders, M. R. (1987). Strategic approaches to drug design. I. An integrated software framework for molecular modelling. Journal of Computer-Aided Molecular Design, 1(1), 31–51. 10.1007/bf01680556
   PubMedGoogle Scholar
• Weir, H. M., Bradbury, R. H., Lawson, M., Rabow, A. A., Buttar, D., Callis, R. J., Curwen, J. O., de Almeida, C., Ballard, P., Hulse, M., Donald, C. S., Feron, L. J. L., Karoutchi, G., MacFaul, P., Moss, T., Norman, R. A., Pearson, S. E., Tonge, M., Davies, G., … De Savi, C. (2016). AZD9496: An oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models. Cancer Research, 76(11), 3307–3318. 10.1158/0008-5472.can-15-2357
   PubMed Web of Science ®Google Scholar
• Wold, S., Sjöström, M., & Eriksson, L. (2001). PLS-regression: A basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems, 58(2), 109–130. 10.1016/s0169-7439(01)00155-1
   Web of Science ®Google Scholar
• Xiong, R., Zhao, J., Gutgesell, L. M., Wang, Y., Lee, S., Karumudi, B., Zhao, H., Lu, Y., Tonetti, D. A., & Thatcher, G. R. J. (2017). Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer. Journal of Medicinal Chemistry, 60(4), 1325–1342. 10.1021/acs.jmedchem.6b01355
   PubMed Web of Science ®Google Scholar
• Yinli, G., Hanxun, W., Jian, W., & Maosheng, C. (2019). In silico studies on p21-activated kinase 4 inhibitors: Comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations and MM-GBSA calculation. Journal of Biomolecular Structure and Dynamics, 1–26. 10.1080/07391102.2019.1673823
   Web of Science ®Google Scholar
• Zheng, L. H., Zhao, Y. H., Feng, H. L., & Liu, Y. J. (2014). Endocrine resistance in breast cancer. Climacteric, 17(5), 522–528. 10.3109/13697137.2013.864268
   PubMed Web of Science ®Google Scholar